

# ACR–SAR–SPR PRACTICE PARAMETER FOR THE PERFORMANCE OF MAGNETIC RESONANCE IMAGING (MRI) OF THE LIVER

The American College of Radiology, with more than 40,000 members, is the principal organization of radiologists, radiation oncologists, and clinical medical physicists in the United States. The College is a nonprofit professional society whose primary purposes are to advance the science of radiology, improve radiologic services to the patient, study the socioeconomic aspects of the practice of radiology, and encourage continuing education for radiologists, radiation oncologists, medical physicists, and persons practicing in allied professional fields.

The American College of Radiology will periodically define new practice parameters and technical standards for radiologic practice to help advance the science of radiology and to improve the quality of service to patients throughout the United States. Existing practice parameters and technical standards will be reviewed for revision or renewal, as appropriate, on their fifth anniversary or sooner, if indicated.

Each practice parameter and technical standard, representing a policy statement by the College, has undergone a thorough consensus process in which it has been subjected to extensive review and approval. The practice parameters and technical standards recognize that the safe and effective use of diagnostic and therapeutic radiology requires specific training, skills, and techniques, as described in each document. Reproduction or modification of the published practice parameter and technical standard by those entities not providing these services is not authorized.

## PREAMBLE

This document is an educational tool designed to assist practitioners in providing appropriate radiologic care for patients. Practice Parameters and Technical Standards are not inflexible rules or requirements of practice and are not intended, nor should they be used, to establish a legal standard of care<sup>1</sup>. For these reasons and those set forth below, the American College of Radiology and our collaborating medical specialty societies caution against the use of these documents in litigation in which the clinical decisions of a practitioner are called into question.

The ultimate judgment regarding the propriety of any specific procedure or course of action must be made by the practitioner considering all the circumstances presented. Thus, an approach that differs from the guidance in this document, standing alone, does not necessarily imply that the approach was below the standard of care. To the contrary, a conscientious practitioner may responsibly adopt a course of action different from that set forth in this document when, in the reasonable judgment of the practitioner, such course of action is indicated by variables such as the condition of the patient, limitations of available resources, or advances in knowledge or technology after publication of this document. However, a practitioner who employs an approach substantially different from the guidance in this document may consider documenting in the patient record information sufficient to explain the approach taken.

The practice of medicine involves the science, and the art of dealing with the prevention, diagnosis, alleviation, and treatment of disease. The variety and complexity of human conditions make it impossible to always reach the most appropriate diagnosis or to predict with certainty a particular response to treatment. Therefore, it should be recognized that adherence to the guidance in this document will not assure an accurate diagnosis or a successful outcome. All that should be expected is that the practitioner will follow a reasonable course of action based on current knowledge, available resources, and the needs of the patient to deliver effective and safe medical care. The purpose of this document is to assist practitioners in achieving this objective.

---

<sup>1</sup> *Iowa Medical Society and Iowa Society of Anesthesiologists v. Iowa Board of Nursing*, 831 N.W.2d 826 (Iowa 2013) Iowa Supreme Court refuses to find that the "ACR Technical Standard for Management of the Use of Radiation in Fluoroscopic Procedures (Revised 2008)" sets a national standard for who may perform fluoroscopic procedures in light of the standard's stated purpose that ACR standards are educational tools and not intended to establish a legal standard of care. See also, *Stanley v. McCarver*, 63 P.3d 1076 (Ariz. App. 2003) where in a concurring opinion the Court stated that "published standards or guidelines of specialty medical organizations are useful in determining the duty owed or the standard of care applicable in a given situation" even though ACR standards themselves do not establish the standard of care.

## I. INTRODUCTION

Magnetic resonance imaging (MRI) of the liver is a proven and useful tool for the evaluation, assessment of severity, and follow-up of diseases of the liver. Although liver MRI is one of the most sensitive diagnostic tests for detection and characterization of hepatic lesions, findings may be misleading if not closely correlated with the results of previous imaging studies, clinical history, physical examination, or laboratory tests. Adherence to the following parameters will enhance the probability of accurately assessing such abnormalities.

## II. INDICATIONS

Indications for MRI of the liver include, but are not limited to, the following:

1. Detection of focal hepatic lesions
2. Focal hepatic lesion characterization (eg, cyst, focal fat, hemangiomas, and vascular malformations), hepatocellular carcinoma (HCC), hepatoblastoma, metastasis, intrahepatic cholangiocarcinoma, focal nodular hyperplasia, and hepatic adenoma
3. Evaluation for known or suspected metastases, including preoperative mapping for liver resection
4. Evaluation of vascular patency, including Budd-Chiari and portal vein thrombosis
5. Evaluation and noninvasive quantification of iron, fat, and fibrosis in chronic liver disease, such as hemochromatosis, hemosiderosis, nonalcoholic steatohepatitis, (NASH) and hepatitis in adults and pediatric patients
6. Evaluation of cirrhotic liver and HCC surveillance
7. Clarification of findings from other imaging studies, laboratory abnormalities, or alternative imaging for contraindications to CT scans
8. Staging of liver and biliary cancers, including assessment of vascular and biliary invasion
9. Evaluation of infection
10. Potential liver donor evaluation, liver resection evaluation, liver transplant evaluation, and evaluation of postsurgical complications
11. Evaluation of tumor response to treatment, eg, image-guided liver interventions/tumor ablation, chemoembolization, radioembolization, chemotherapy, radiotherapy, or surgery
12. Evaluation of known or suspected congenital abnormalities
13. Informing or guiding clinical decision making and treatment planning

## III. QUALIFICATIONS AND RESPONSIBILITIES OF PERSONNEL

See the [ACR Practice Parameter for Performing and Interpreting Magnetic Resonance Imaging \(MRI\)](#) [1].

## IV. SPECIFICATIONS OF THE EXAMINATION

The written or electronic request for MRI of the liver should provide sufficient information to demonstrate the medical necessity of the examination and allow for the proper performance and interpretation of the examination.

Documentation that satisfies medical necessity includes 1) signs and symptoms and/or 2) relevant history (including known diagnoses). The provision of additional information regarding the specific reason for the examination or a provisional diagnosis would be helpful and may at times be needed to allow for the proper performance and interpretation of the examination.

The request for the examination must be originated by a physician or other appropriately licensed health care provider. The accompanying clinical information should be provided by a physician or other appropriately licensed health care provider familiar with the patient's clinical problem or question and consistent with the state scope of practice requirements. (ACR Resolution 35 adopted in 2006 – revised in 2016, Resolution 12-b)

The supervising physician must have adequate understanding of the indications, risks, and benefits of the examination as well as alternative imaging procedures. The physician must be familiar with potential hazards associated with MRI, including potential adverse reactions to contrast media. The physician should be familiar with relevant prior ancillary studies. The physician performing MRI interpretation must have a clear understanding

and knowledge of the relevant anatomy and pathophysiology.

The supervising physician must also understand the pulse sequences to be used and their effect on the appearance of the images, including the potential generation of image artifacts. It is also critical to understand the different contrast agents used for liver MRI as well as the basis for choosing between them. Standard imaging protocols may be established and varied on a case-by-case basis when necessary. These protocols should be reviewed and updated periodically.

#### A. Patient Selection

The physician responsible for the examination should supervise patient selection and preparation and be available for consultation by direct communication. Patients must be screened and interviewed prior to the examination to exclude individuals who may have contraindications to MRI, in which the risks may outweigh the benefits (see the [ACR Guidance Document on MR Safe Practices 2020 \[2\]](#)).

Certain indications require administration of intravenous (IV) contrast media. IV contrast administration should be performed using appropriate injection protocols and in accordance with the institution's policy on IV contrast utilization (see the [ACR-SPR Practice Parameter for the Use of Intravascular Contrast Media \[3\]](#)).

Patients suffering from anxiety or claustrophobia or who are unable to cooperate or suspend respiration, such as children, may require sedation or additional assistance. Administration of sedation may be necessary to achieve a diagnostic examination. If sedation is necessary, refer to the [ACR-SIR Practice Parameter for Sedation/Analgesia \[4\]](#) and the American Academy of Pediatrics (AAP) - American Academy of Pediatric Dentistry (AAPD): Guidelines for Monitoring and Management of Pediatric Patients During and After Sedation for Diagnostic and Therapeutic procedures [5].

#### B. Facility Requirements

Appropriate emergency equipment and medications must be immediately available to treat adverse reactions associated with administered medications. The equipment and medications should be monitored for inventory and drug expiration dates on a regular basis. The equipment, medications, and other emergency support must also be appropriate for the range of ages and sizes in the patient population.

#### C. Examination Technique

A phased array surface coil should be used [6] unless precluded by patient body habitus or scan indication. The field of view should be selected so that it includes the entire liver without introducing undesirable artifacts.

An adequate MRI examination of the liver is typically performed in the axial plane, and coronal plane images are added as necessary to improve the visualization of the liver dome, vasculature, and bile ducts and to facilitate interventional and surgical planning.

An adequate MRI examination of the liver should include T2-weighted imaging, which may be performed with an accelerated fast spin-echo, single-shot accelerated fast spin-echo (FSE), or steady-state free precession sequence (in axial and/or coronal planes). T2-weighted images can be obtained using a breath-hold or non-breath-hold technique. When a non-breath-hold technique is used, every effort should be made to minimize the respiratory motion artifacts by using multiple signal averages and/or respiratory compensation or respiratory triggering, which could include bellows or navigator-triggered sequence. Other motion-correction strategies, including periodically rotated overlapping parallel lines, may be useful. For effective T2-weighting, an echo time (TE) between approximately 80 and 100 ms should be used at 1.5T and 70–100 ms at 3T. T2-weighted images are helpful to show abnormal increased fluid or inflammation in diseased tissue and fluid-containing lesions (eg, cysts, biliary hamartoma, hemangiomas, and vascular malformations) [7]. When using a 2-D technique, the slice thickness and interslice gap in one of the planes should not exceed 8 and 2 mm, respectively. Parallel MRI with suitable phased-array coils is often used to reduce scan time and increase spatial resolution. Fat suppression may be helpful to assess for fluid and inflammation and to improve image contrast dynamic range.

IV contrast enhancement with gadolinium chelates is critical for accurate diagnosis of various liver

pathologies [8]. Use of IV contrast should be strongly considered except when there is a) no IV access, b) history of prior allergic-type reaction to gadolinium chelates and the patient has not been premedicated prior to the study, c) contraindication to gadolinium chelates (such as pregnancy), d) known or suspected nephrogenic systemic fibrosis (NSF) or particular concerns regarding NSF risk that outweigh the benefits of a contrast-enhanced liver MR, or e) contrast is not felt to be necessary for the diagnosis in question [2,9,10]. In patients with a high risk of NSF in whom contrast is not used, an unenhanced MR could still be helpful. Long-term safety of gadolinium-based contrast agent (GBCA) administration is not yet established, especially in young infants. A cautious risk/benefit approach is desirable with avoidance of GBCA when feasible in young infants. When contrast administration is required, lower dosing and macrocyclic agents should be considered. Dynamic fat-suppressed MRI should be performed after bolus administration of a gadolinium chelate contrast agent. T1-weighted images should be acquired before gadolinium contrast injection as well as during late hepatic arterial, portal venous, and 2- to 5-minute delayed phases using a 2-D or 3-D technique [11,12]. The 3-D techniques are preferred. Methods to obtain late hepatic arterial phase include using a bolus timing technique, such as automated bolus detection algorithm or fluoroscopic triggering, or obtaining multiple consecutive arterial-phase data sets with higher temporal but lower spatial resolution. An optimal late arterial phase is characterized by the following:

- Hepatic artery and branches are fully enhanced
- Hepatic veins not yet enhanced by antegrade flow
- Portal vein is enhanced

Additional delayed images with delays greater than 2 to 5 minutes may help characterize certain lesions, such as HCC, hemangiomas, and vascular malformations, or intrahepatic cholangiocarcinomas [13-15]. Fat-suppressed 3-D T1-weighted gradient-echo images have quality comparable to that of conventional fat-suppressed 2-D gradient-echo images [16]. It is advantageous to acquire 3-D data sets using the smallest voxel dimensions possible to achieve the highest resolution practical in each axis. Minimizing slice thickness of a volumetric acquisition can reduce truncation artifacts in the axis of slice encoding, which can be a source of boundary artifacts at high-contrast borders. When using a 2-D technique, the slice thickness and interslice gap should not exceed 8 and 2 mm, respectively.

Hepatobiliary phase (HBP) images obtained between 45 minutes and 3 hours after the administration of gadobenate dimeglumine and approximately 20 minutes after the administration of gadoxetate disodium revealing retention of contrast within the lesion can confirm the diagnosis of focal nodular hyperplasia [18-20]. HBP images can also be used to detect and characterize malignant disease and assess its extent [21-23]. The use of hepatobiliary agents partially excreted in the biliary system, such as gadoxetate and gadobenate, can help delineate biliary anatomy [26-28]. When interpreting HBP images, it is important to ascertain the adequacy for diagnosis. For an adequate HBP image in patients without chronic liver disease, the liver parenchyma is unequivocally brighter than the intrahepatic blood vessels; otherwise, the HBP images are considered suboptimal. Poor enhancement of hepatic parenchyma may be seen in some patients with chronic liver disease. The use of hepatobiliary agents may not be advisable in patients with total bilirubin of greater than 2 mg/mL [24-26]. T2-weighted imaging of the biliary tree (Magnetic resonance cholangiopancreatography (MRCP) images) must be completed before contrast is excreted into bile ducts because gadolinium within the bile can shorten the T2 and result in the biliary tree not being visible on MRCP images. This can be prevented by obtaining MRCP images before or within 5 minutes after administration of gadoxetate or within several minutes after administering gadobenate dimeglumine. T2-weighted and diffusion-weighted images can be obtained after injection of gadoxetate disodium to improve time efficiency, and diffusion-weighted imaging (DWI) sequences may be delayed more than 5 minutes after HBP agents.

In-phase and out-of-phase chemical shift gradient-recalled echo T1-weighted imaging should be included for lesion characterization and for confirmation of hepatic steatosis and iron overload; these sequences should be obtained prior to the administration of IV contrast material [27]. Out-of-phase images can be helpful to assess for signal loss from fat in fat-containing lesions, such as hepatic adenomas and HCC. Every effort should be made to ensure that the out-of-phase TE is shorter than the in-phase TE. Note that in livers with simultaneous iron overload and steatosis, a potential pitfall exists in which in-phase and out-of-phase imaging may show no comparative signal loss (ie, signal loss due to steatosis on the out-of-phase image may be counterbalanced by signal loss due to iron overload on the in-phase image). Another pitfall may occur when in-phase images have a shorter TE than out-of-phase images. In these instances, signal loss on

the out-of-phase echo could be from iron overload, steatosis, or a combination of both. In addition, the TEs for the in-phase and out-of-phase images at 3T are half that at 1.5T, which needs to be accounted for when assessing for fat or iron. A number of techniques have been developed, tested, and validated for quantitative measurement of liver iron and fat content [28-32]. These methods have been commercialized by many MR vendors and are available clinically for quantitative measure of liver iron and fat. The current gold standard for fat quantification with MRI is proton density fat fraction (PDFF). PDFF is the proportion of mobile protons in liver tissue attributable to fat and thus is a noninvasive MR-based biomarker of liver triglyceride concentration.

3T imaging systems are more widely available. Potential advantages of 3T systems include an increased signal-to-noise ratio (SNR) [33] and an increased conspicuity of enhancement after administration of a gadolinium chelate contrast agent [34]. Potential disadvantages include decreased image contrast on T1-weighted images, increased predisposition to susceptibility artifact, increased chemical shift artifact, increased specific absorption rate, and signal inhomogeneity [35]. The latter can be partially compensated for by the use of radiofrequency (RF) cushions [36] and/or parallel transmit technology. In short, 3T imaging can offer substantial improvements in SNR and spatial resolution and/or decreases in imaging times, but sequence modifications are often required to maintain desired image contrast and reduce artifacts [37,38]. However, in patients with obesity or those with cirrhosis, 1.5T MRI may be considered because of the standing wave and dielectric artifacts seen on 3T MRI.

DWI has become commonly used for abdominal protocols [39-44]. The most common technique uses single-shot echo-planar imaging (SS-EPI). Breath-held, free breathing multiple-averaging, and respiratory-gated SS-EPI techniques can be used [45,46]. Parallel imaging can be used to decrease imaging time and has been shown to result in accurate apparent diffusion coefficient (ADC) values [47]. DWI has shown promising results in detection and characterization of focal liver lesions, in detection and staging of liver fibrosis, and appears to be at least a value-added adjunct sequence capable of revealing additional sites of disease in the abdomen [48,49]. The ability to depict areas of high cellularity can be helpful in hepatic lesion detection and in characterization in a noninvasive manner. DWI does not rely on IV gadolinium; therefore, its use is particularly attractive in patients who are unable to receive IV contrast agents. ADC maps can be generated to help differentiate between restricted diffusion and T2 shine-through. At least 2 b-values are obtained, including  $b = 20\text{--}50 \text{ s/mm}^2$  and  $b = 400 \text{ to } 1,000 \text{ s/mm}^2$ . However, overlap exists between ADC values of solid benign hepatocellular lesions, such as focal nodular hyperplasia (FNH) or hepatocellular adenoma (HCA), and those of malignant lesions [40,43,50-56]. Thus, information provided by DWI needs to be interpreted in conjunction with lesion morphology and signal characteristics on other sequences. Moreover, ADC values are technique and scanner dependent; diagnostic cutoff values reported in the literature may not be applicable to other scanners. Techniques such as simultaneous multislice (SMS) technique may allow DWI to be performed in under one minute [57].

MR elastography (MRE) is a technique that enables measurement of liver stiffness. Published data over the last 5 years show that this method has high accuracy in discriminating different stages of liver fibrosis [58-62].

## V. DOCUMENTATION

Reporting should be in accordance with the [ACR Practice Parameter for Communication of Diagnostic Imaging Findings](#) [63].

In patients at high risk for HCC, please refer to the Liver Imaging Reporting and Data System (LI-RADS) (<http://www.acr.org/Quality-Safety/Resources/LIRADS>) for additional guidance on reporting of MRI in this population.

Specific policies and procedures related to MRI safety should be in place with documentation that is updated annually and compiled under the supervision and direction of the supervising MRI physician. Guidelines should be provided that deal with potential hazards associated with MRI examination of the patient as well as to others in the immediate area [64-73]. Screening forms must also be provided to detect those patients who may be at risk for adverse events associated with the MRI examination [64-73].

## VI. EQUIPMENT SPECIFICATIONS

Equipment monitoring should be in accordance with the [ACR-AAPM Technical Standard for Diagnostic Medical Physics Performance Monitoring of Magnetic Resonance Imaging \(MRI\) Equipment \[74\]](#).

The MRI equipment specifications and performance must meet all state and federal requirements. The requirements include, but are not limited to, specifications of maximum static magnetic strength, maximum rate of change of magnetic field strength (dB/dt), maximum RF power deposition (specific absorption rate), and maximum acoustic noise levels.

**VII.  
QUALITY CONTROL AND IMPROVEMENT, SAFETY, INFECTION CONTROL, AND PATIENT EDUCATION**

Policies and procedures related to quality, patient education, infection control, and safety should be developed and implemented in accordance with the ACR Policy on Quality Control and Improvement, Safety, Infection Control, and Patient Education appearing under the heading *ACR Position Statement on Quality Control and Improvement, Safety, Infection Control, and Patient Education* on the ACR website (<https://www.acr.org/Advocacy-and-Economics/ACR-Position-Statements/Quality-Control-and-Improvement>).

Peer-reviewed literature pertaining to MR safety should be reviewed on a regular basis [4-13]

**ACKNOWLEDGEMENTS**

This practice parameter was revised according to the process described under the heading *The Process for Developing ACR Practice Parameters and Technical Standards* on the ACR website (<https://www.acr.org/Clinical-Resources/Practice-Parameters-and-Technical-Standards>) by the Committee on Body Imaging (Abdominal) of the Commission on Body Imaging and by the Committee on Practice Parameters – Pediatric Radiology of the Commission on Pediatric Radiology, in collaboration with the Society of Abdominal Radiology (SAR) and the Society for Pediatric Radiology (SPR).

Collaborative Committee

<u>ACR</u>	<u>SAR</u>	<u>SPR</u>
Hersh Chandarana, MD, Chair	Victoria Chernyak, MD, MS	Govind B. Chavhan, MD
Tara M. Catanzano, MD, FSCBTMR	Kartik Jhaveri, MD	Nathan Hull, MD
Frank H. Miller, MD, FACR	Sudhakar Venkatesh, MD	Gary Schooler, MD
Avinash Kambadakone Ramesh, MD		

Committee on Practice Parameters - Body Imaging (Abdominal)

(ACR Committee responsible for sponsoring the draft through the process)

Benjamin M Yeh, MD, Chair

Diego Martin, MD, PhD

Mahmoud M. Al-Hawary, MD

Alec Megibow, MD, MPH, FACR

Mark E. Baker, MD, FACR

Achille Mileto, MD

Olga Brooks, MD

Erick Remer, MD, FACR

Lindsay Busby MD, MPH

Kumar Sandrasegaran, MD

Jay P. Heiken MD, FACR

Adam Stephen Young, MD, MBA

David Kim, MD, FACR

Committee on Practice Parameters – Pediatric Radiology

(ACR Committee responsible for sponsoring the draft through the process)

Beverley Newman, MB, BCh, BSc, FACR, Chair

Jason Higgins, DO

Terry L. Levin, MD, FACR, Vice Chair

Jane Sun Kim, MD

John B. Amodio, MD, FACR

Jessica Kurian, MD

Tara M. Catanzano, MB, BCh

Matthew P. Lungren, MD, MPH

Harris L. Cohen, MD, FACR

Helen R. Nadel, MD

Kassa Darge, MD, PhD

Erica Poletto, MD

Dorothy L. Gilbertson-Dahdal, MD

Richard B. Towbin, MD, FACR

Lauren P. Golding, MD

Andrew T. Trout, MD

Safwan S. Halabi, MD

Esben S. Vogelius, MD

Lincoln L. Berland, MD, FACR, Chair, Commission on Body Imaging

Richard A. Barth, MD, FACR, Chair, Commission on Pediatric Radiology

Jacqueline A. Bello, MD, FACR, Chair, Commission on Quality and Safety

Mary S. Newell, MD, FACR, Chair, Committee on Practice Parameters and Technical Standards

Comments Reconciliation Committee

Elaine Lewis, MD, FACR – Chair

Kartik Jhaveri, MD

Andy Moriarity, MD – Vice Chair

David H. Kim, MD, FACR

Richard A. Barth, MD, FACR

Amy L. Kotsenas, MD

Jacqueline Anne Bello, MD

Paul A. Larson, MD, FACR

Lincoln L. Berland, MD, FACR

Pradnya Y. Mhatre, MD

Priyadarshani R. Bhosale, MD

Frank H. Miller, MD, FACR

Tara M. Catanzano, MD, BCh

Mary S. Newell, MD

Hersh Chandarana, MD

Beverley Newman, MB, BCh, BSc, FACR

Govind B. Chavhan, MD

Avinash K. Ramesh, MD

Victoria Chernyak, MD

Erick M. Remer, MD, FACR

Richard Duszak, Jr., MD

Kumaresan Sandrasegaran, MD

Christopher Fung, MD

Gary Schooler, MD

Mauro M. Hanaoka, MD

Sudhakar Venkatesh, MD

Nathan Hull, MD

Benjamin M. Yeh, MD



## REFERENCES

1. American College of Radiology. ACR Practice Parameter for Performing and Interpreting Magnetic Resonance Imaging (MRI). Available at: <https://www.acr.org/-/media/ACR/Files/Practice-Parameters/MR-Perf-Interpret.pdf>. Accessed March 5, 2019.
2. American College of Radiology. ACR guidance document on MR safe practices: 2020. 05/15/2020; Available at: <https://www.acr.org/-/media/ACR/Files/Radiology-Safety/MR-Safety/Manual-on-MR-Safety.pdf>. Accessed June 26, 2020.
3. American College of Radiology. ACR–SPR Practice Parameter for the Use of Intravascular Contrast Media. Available at: <https://www.acr.org/-/media/ACR/Files/Practice-Parameters/IVCM.pdf>. Accessed March 5, 2019.
4. American College of Radiology. ACR–SIR Practice Parameter for Sedation/Analgesia. Available at: <https://www.acr.org/-/media/ACR/Files/Practice-Parameters/Sed-Analgesia.pdf>. Accessed March 5, 2019.
5. Cote CJ, Wilson S, American Academy Of P, American Academy Of Pediatric D. Guidelines for Monitoring and Management of Pediatric Patients Before, During, and After Sedation for Diagnostic and Therapeutic Procedures: Update 2016. *Pediatrics* 2016;138.
6. Helmberger T, Holzkecht N, Lackerbauer CA, et al. [Phased-array superficial coil and breath holding technique in MRI of the liver. Comparison of conventional spin echo sequences with rapid fat suppressing gradient echo and turbo-spin sequences]. *Der Radiologe* 1995;35:919-24.
7. Bong SK WA, Yong-Hwan J, Richard C. Semelka. Body MR Imaging: Fast, Efficient, and Comprehensive. *Radiologic Clinics of North America* 2014;52:623-36.
8. Yamashita Y, Hatanaka Y, Yamamoto H, et al. Differential diagnosis of focal liver lesions: role of spin-echo and contrast-enhanced dynamic MR imaging. *Radiology* 1994;193:59-65.
9. Broome DR, Girguis MS, Baron PW, Cottrell AC, Kjellin I, Kirk GA. Gadodiamide-associated nephrogenic systemic fibrosis: why radiologists should be concerned. *AJR. American journal of roentgenology* 2007;188:586-92.
10. American College of Radiology. Manual on Contrast Media. [http://www.acr.org/SecondaryMainMenuCategories/quality\\_safety/contrast\\_manual.aspx](http://www.acr.org/SecondaryMainMenuCategories/quality_safety/contrast_manual.aspx). Accessed March 5, 2019.
11. Mitchell DG, Palazzo J, Hann HW, Rifkin MD, Burk DL, Jr., Rubin R. Hepatocellular tumors with high signal on T1-weighted MR images: chemical shift MR imaging and histologic correlation. *Journal of computer assisted tomography* 1991;15:762-9.
12. Semelka RC, Helmberger TK. Contrast agents for MR imaging of the liver. *Radiology* 2001;218:27-38.
13. Runge VM. A comparison of two MR hepatobiliary gadolinium chelates: Gd-BOPTA and Gd-EOB-DTPA. *Journal of computer assisted tomography* 1998;22:643-50.
14. Semelka RC, Brown ED, Ascher SM, et al. Hepatic hemangiomas: a multi-institutional study of appearance on T2-weighted and serial gadolinium-enhanced gradient-echo MR images. *Radiology* 1994;192:401-6.
15. Soyer P, Bluemke DA, Reichle R, et al. Imaging of intrahepatic cholangiocarcinoma: 2. Hilar cholangiocarcinoma. *AJR. American journal of roentgenology* 1995;165:1433-6.
16. Rofsky NM, Lee VS, Laub G, et al. Abdominal MR imaging with a volumetric interpolated breath-hold examination. *Radiology* 1999;212:876-84.
17. Chandarana H, Block KT, Winfeld MJ, et al. Free-breathing contrast-enhanced T1-weighted gradient-echo imaging with radial k-space sampling for paediatric abdominopelvic MRI. *European radiology* 2014;24:320-6.
18. Grazioli L, Morana G, Kirchin MA, Schneider G. Accurate differentiation of focal nodular hyperplasia from hepatic adenoma at gadobenate dimeglumine-enhanced MR imaging: prospective study. *Radiology* 2005;236:166-77.
19. Zech CJ, Grazioli L, Breuer J, Reiser MF, Schoenberg SO. Diagnostic performance and description of morphological features of focal nodular hyperplasia in Gd-EOB-DTPA-enhanced liver magnetic resonance imaging: results of a multicenter trial. *Investigative radiology* 2008;43:504-11.
20. Goodwin MD, Dobson JE, Sirlin CB, Lim BG, Stella DL. Diagnostic challenges and pitfalls in MR imaging with hepatocyte-specific contrast agents. *Radiographics : a review publication of the Radiological Society of North America, Inc* 2011;31:1547-68.
21. Duncan JK, Ma N, Vreugdenburg TD, Cameron AL, Maddern G. Gadoteric acid-enhanced MRI for the

- characterization of hepatocellular carcinoma: A systematic review and meta-analysis. *Journal of Magnetic Resonance Imaging* 2017;45:281-90.
22. Jhaveri KS, Fischer SE, Hosseini-Nik H, et al. Prospective comparison of gadoxetic acid-enhanced liver MRI and contrast-enhanced CT with histopathological correlation for preoperative detection of colorectal liver metastases following chemotherapy and potential impact on surgical plan. *HPB* 2017;19:992-1000.
  23. Vilgrain V, Esvan M, Ronot M, Caumont-Prim A, Aube C, Chatellier G. A meta-analysis of diffusion-weighted and gadoxetic acid-enhanced MR imaging for the detection of liver metastases. *European radiology* 2016;26:4595-615.
  24. Hope TA, Fowler KJ, Sirlin CB, et al. Hepatobiliary agents and their role in LI-RADS. *Abdominal imaging* 2015;40:613-25.
  25. Chernyak V, Fowler KJ, Heiken JP, Sirlin CB. Use of gadoxetate disodium in patients with chronic liver disease and its implications for liver imaging reporting and data system (LI-RADS). *Journal of magnetic resonance imaging : JMRI* 2019;49:1236-52.
  26. American College of Radiology. Hepatobiliary Agents. *LI-RADS CT/MRI Manual* [Available at: <https://www.acr.org/-/media/ACR/Files/Clinical-Resources/LIRADS/Chapter-13-HBA.pdf?la=en>. Accessed June 19, 2019.
  27. Heiken JP, Lee JK, Dixon WT. Fatty infiltration of the liver: evaluation by proton spectroscopic imaging. *Radiology* 1985;157:707-10.
  28. Artz NS, Haufe WM, Hooker CA, et al. Reproducibility of MR-based liver fat quantification across field strength: Same-day comparison between 1.5T and 3T in obese subjects. *Journal of Magnetic Resonance Imaging* 2015;42:811-17.
  29. Satkunasingham J, Besa C, Bane O, et al. Liver fat quantification: Comparison of dual-echo and triple-echo chemical shift MRI to MR spectroscopy. *European Journal of Radiology* 2015;84:1452-58.
  30. Hernando D, Levin YS, Sirlin CB, Reeder SB. Quantification of liver iron with MRI: State of the art and remaining challenges. *Journal of Magnetic Resonance Imaging* 2014;40:1003-21.
  31. Kühn J-P, Hernando D, Mensel B, et al. Quantitative chemical shift-encoded MRI is an accurate method to quantify hepatic steatosis. *Journal of Magnetic Resonance Imaging* 2014;39:1494-501.
  32. Yokoo T, Shiehorteza M, Hamilton G, et al. Estimation of hepatic proton-density fat fraction by using MR imaging at 3.0 T. *Radiology* 2011;258:749-59.
  33. Choi JY, Kim MJ, Chung YE, et al. Abdominal applications of 3.0-T MR imaging: comparative review versus a 1.5-T system. *Radiographics : a review publication of the Radiological Society of North America, Inc* 2008;28:e30.
  34. Soher BJ, Dale BM, Merkle EM. A review of MR physics: 3T versus 1.5T. *Magnetic resonance imaging clinics of North America* 2007;15:277-90, v.
  35. Leyendecker JR, Childs DD. Kidneys and MR urography. *Magnetic resonance imaging clinics of North America* 2007;15:373-82, vii.
  36. Franklin KM, Dale BM, Merkle EM. Improvement in B1-inhomogeneity artifacts in the abdomen at 3T MR imaging using a radiofrequency cushion. *Journal of magnetic resonance imaging : JMRI* 2008;27:1443-7.
  37. Chang KJ, Kamel IR, Macura KJ, Bluemke DA. 3.0-T MR imaging of the abdomen: comparison with 1.5 T. *Radiographics : a review publication of the Radiological Society of North America, Inc* 2008;28:1983-98.
  38. Erturk SM, Alberich-Bayarri A, Herrmann KA, Marti-Bonmati L, Ros PR. Use of 3.0-T MR imaging for evaluation of the abdomen. *Radiographics : a review publication of the Radiological Society of North America, Inc* 2009;29:1547-63.
  39. Koh DM, Collins DJ. Diffusion-weighted MRI in the body: applications and challenges in oncology. *AJR. American journal of roentgenology* 2007;188:1622-35.
  40. Parikh T, Drew SJ, Lee VS, et al. Focal liver lesion detection and characterization with diffusion-weighted MR imaging: comparison with standard breath-hold T2-weighted imaging. *Radiology* 2008;246:812-22.
  41. Taouli B. Diffusion-weighted MR imaging for liver lesion characterization: a critical look. *Radiology* 2012;262:378-80.
  42. Taouli B, Koh DM. Diffusion-weighted MR imaging of the liver. *Radiology* 2010;254:47-66.
  43. Taouli B, Vilgrain V, Dumont E, Daire JL, Fan B, Menu Y. Evaluation of liver diffusion isotropy and characterization of focal hepatic lesions with two single-shot echo-planar MR imaging sequences: prospective study in 66 patients. *Radiology* 2003;226:71-8.
  44. de Souza DA, Parente DB, de Araujo AL, Morteale KJ. Modern imaging evaluation of the liver: emerging MR

- imaging techniques and indications. *Magnetic resonance imaging clinics of North America* 2013;21:337-63.
45. Gourtsoyianni S, Papanikolaou N, Yarmenitis S, Maris T, Karantanis A, Gourtsoyiannis N. Respiratory gated diffusion-weighted imaging of the liver: value of apparent diffusion coefficient measurements in the differentiation between most commonly encountered benign and malignant focal liver lesions. *European radiology* 2008;18:486-92.
  46. Koh DM, Takahara T, Imai Y, Collins DJ. Practical aspects of assessing tumors using clinical diffusion-weighted imaging in the body. *Magnetic resonance in medical sciences : MRMS : an official journal of Japan Society of Magnetic Resonance in Medicine* 2007;6:211-24.
  47. Yoshikawa T, Kawamitsu H, Mitchell DG, et al. ADC measurement of abdominal organs and lesions using parallel imaging technique. *AJR. American journal of roentgenology* 2006;187:1521-30.
  48. Low RN, Gurney J. Diffusion-weighted MRI (DWI) in the oncology patient: value of breathhold DWI compared to unenhanced and gadolinium-enhanced MRI. *Journal of magnetic resonance imaging : JMRI* 2007;25:848-58.
  49. Lewin M, Poujol-Robert A, Boelle PY, et al. Diffusion-weighted magnetic resonance imaging for the assessment of fibrosis in chronic hepatitis C. *Hepatology* 2007;46:658-65.
  50. Bruegel M, Holzapfel K, Gaa J, et al. Characterization of focal liver lesions by ADC measurements using a respiratory triggered diffusion-weighted single-shot echo-planar MR imaging technique. *European radiology* 2008;18:477-85.
  51. Miller FH, Hammond N, Siddiqi AJ, et al. Utility of diffusion-weighted MRI in distinguishing benign and malignant hepatic lesions. *Journal of magnetic resonance imaging : JMRI* 2010;32:138-47.
  52. Agnello F, Ronot M, Valla DC, Sinkus R, Van Beers BE, Vilgrain V. High-b-value diffusion-weighted MR imaging of benign hepatocellular lesions: quantitative and qualitative analysis. *Radiology* 2012;262:511-9.
  53. Cieszanowski A, Anysz-Grodzicka A, Szeszkowski W, et al. Characterization of focal liver lesions using quantitative techniques: comparison of apparent diffusion coefficient values and T2 relaxation times. *European radiology* 2012;22:2514-24.
  54. Sandrasegaran K, Akisik FM, Lin C, Tahir B, Rajan J, Aisen AM. The value of diffusion-weighted imaging in characterizing focal liver masses. *Academic radiology* 2009;16:1208-14.
  55. Caro-Dominguez P, Gupta AA, Chavhan GB. Can diffusion-weighted imaging distinguish between benign and malignant pediatric liver tumors? *Pediatr Radiol* 2018;48:85-93.
  56. Chavhan GB, Shelmerdine S, Jhaveri K, Babyn PS. Liver MR Imaging in Children: Current Concepts and Technique. *Radiographics : a review publication of the Radiological Society of North America, Inc* 2016;36:1517-32.
  57. Taron J, Martirosian P, Erb M, et al. Simultaneous multislice diffusion-weighted MRI of the liver: Analysis of different breathing schemes in comparison to standard sequences. *Journal of magnetic resonance imaging : JMRI* 2016;44:865-79.
  58. Singh S, Venkatesh SK, Wang Z, et al. Diagnostic performance of magnetic resonance elastography in staging liver fibrosis: a systematic review and meta-analysis of individual participant data. *Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association* 2015;13:440-51.e6.
  59. Horowitz JM, Kamel IR, Arif-Tiwari H, et al. ACR Appropriateness Criteria® Chronic Liver Disease. *Journal of the American College of Radiology* 2017;14:S391-S405.
  60. Morisaka H, Motosugi U, Ichikawa S, et al. Magnetic resonance elastography is as accurate as liver biopsy for liver fibrosis staging. *Journal of Magnetic Resonance Imaging* 2018;47:1268-75.
  61. Horowitz JM, Venkatesh SK, Ehman RL, et al. Evaluation of hepatic fibrosis: a review from the society of abdominal radiology disease focus panel. *Abdominal radiology (New York)* 2017;42:2037-53.
  62. Serai SD, Obuchowski NA, Venkatesh SK, et al. Repeatability of MR Elastography of Liver: A Meta-Analysis. *Radiology* 2017;285:92-100.
  63. American College of Radiology. ACR Practice Parameter for Communication of Diagnostic Imaging Findings. June 17:2019. Available at: Available at: <https://www.acr.org/-/media/ACR/Files/Practice-Parameters/CommunicationDiag.pdf>.
  64. Colletti PM. Magnetic resonance procedures and pregnancy. In: Shellock FG, ed. *Magnetic Resonance Procedures: Health Effects and Safety*. Boca Raton, Fla.: CRC Press; 2001.
  65. Finelli DA, Rezai AR, Ruggieri PM, et al. MR imaging-related heating of deep brain stimulation electrodes: in vitro study. *AJNR. American journal of neuroradiology* 2002;23:1795-802.

- Revised 2020 (Resolution 27)
66. de Zeeuw R, van den Broek P, van den Hoven JA, et al. Neurostimulation systems for deep brain stimulation: in vitro evaluation of magnetic resonance imaging-related heating at 1.5 tesla. *Journal of magnetic resonance imaging : JMRI* 2002;15:241-50.
67. Sawyer-Glover AM, Shellock FG. Pre-MRI procedure screening: recommendations and safety considerations for biomedical implants and devices. *Journal of magnetic resonance imaging : JMRI* 2000;12:92-106.
68. Shellock FG. *Magnetic Resonance Procedures: Health Effects and Safety*. Boca Raton, Fla.: CRC Press; 2001.
69. Shellock FG. Magnetic resonance safety update 2002: implants and devices. *Journal of magnetic resonance imaging : JMRI* 2002;16:485-96.
70. Shellock FG. Biomedical implants and devices: assessment of magnetic field interactions with a 3.0-Tesla MR system. *Journal of magnetic resonance imaging : JMRI* 2002;16:721-32.
71. Shellock FG. *Reference Manual for Magnetic Resonance Safety, Implants and Devices*. 2005 ed. Los Angeles, Calif: Biomedical Research Publishing Group; 2005.
72. Shellock FG, Cruess JV. MR procedures: biologic effects, safety, and patient care. *Radiology* 2004;232:635-52.
73. Shellock FG, Tkach JA, Ruggieri PM, Masaryk TJ, Rasmussen PA. Aneurysm clips: evaluation of magnetic field interactions and translational attraction by use of "long-bore" and "short-bore" 3.0-T MR imaging systems. *AJNR. American journal of neuroradiology* 2003;24:463-71.
74. American College of Radiology. ACR-AAPM Technical Standard for Diagnostic Medical Physics Performance Monitoring of Magnetic Resonance Imaging (MRI) Equipment. Available at: <https://www.acr.org/-/media/ACR/Files/Practice-Parameters/MR-Equip.pdf>. Accessed June 17, 2019.

\*Parameters and standards are published annually with an effective date of October 1 in the year in which amended, revised, or approved by the ACR Council. For parameters and standards published before 1999, the effective date was January 1 following the year in which the parameter or standard was amended, revised, or approved by the ACR Council.

#### Development Chronology for this Parameter

2005 (Resolution 3)

Amended 2006 (Resolution 35)

Revised 2010 (Resolution 14)

Amended 2014 (Resolution 39)

Revised 2015 (Resolution 3)

Revised 2020 (Resolution 27)

Amended 2023 (Resolution 2c)